Rep. Carol D. Miller Purchases Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Representative Carol D. Miller (R-West Virginia) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on March 10th. The trade occurred in the Representative's "MATT MILLER INVESTMENT MANAGEMENT ACCOUNT" account.

Representative Carol D. Miller also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Aflac NYSE: AFL on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 3/10/2025.
• Sold $1,001 - $15,000 in shares of Pfizer NYSE: PFE on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of Lockheed Martin NYSE: LMT on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of Honeywell International NASDAQ: HON on 3/10/2025.
• Sold $1,001 - $15,000 in shares of U.S. Bancorp NYSE: USB on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of CME Group NASDAQ: CME on 3/10/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of American Water Works NYSE: AWK on 3/10/2025.

Gilead Sciences Stock Performance

GILD stock traded down $0.39 during midday trading on Friday, reaching $104.49. The company had a trading volume of 8,066,368 shares, compared to its average volume of 7,515,503. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a 50 day moving average price of $108.99 and a 200 day moving average price of $97.30. The firm has a market capitalization of $130.10 billion, a PE ratio of 282.40, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.02%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 854.05%.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently modified their holdings of the stock. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 137,676 shares of the business's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the sale, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 302,785 shares of company stock valued at $30,540,875 over the last three months. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on GILD. Morgan Stanley upped their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Piper Sandler raised their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Finally, DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $105.12.

About Representative Miller

Carol Miller (Republican Party) is a member of the U.S. House, representing West Virginia's 1st Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Miller (Republican Party) ran for re-election to the U.S. House to represent West Virginia's 1st Congressional District. She won in the general election on November 5, 2024. West Virginia's 3rd Congressional District race was identified as a 2018 battleground that might have affected partisan control of the U.S. House in the 116th Congress. Incumbent Evan Jenkins (R) did not seek re-election in 2018, leaving the seat open. In the campaign, Miller emphasized her endorsement by President Donald Trump (R). Lara Trump, Senior Advisor to Donald J. Trump for President, Inc., said, "Carol is pro-coal, pro-Second Amendment, and pro-Trump through and through, and is prepared to tackle the opioid epidemic that’s affected countless West Virginians." Miller also supported the construction of a wall on the southern U.S. border and the Tax Cuts and Jobs Act (TCJA). Miller is a former Republican member of the West Virginia House of Delegates, representing District 16 from 2006 to 2018. Miller has also worked in real estate and owns a bison farm. Carol Miller was born in Columbus, Ohio. Miller graduated from Bexley High School in 1968. She earned a B.S. from Columbia College in 1972. Her career experience includes owning and operating Swann Ridge Bison Farm and working as a real estate manager.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.